Phaseline

Targets › IL4R

IL4R (Interleukin-4 receptor subunit alpha): drug programs, companies and trials

13 programs from 13 companies in 159 trials: 61 Phase 2, 36 Phase 4, 33 Phase 3, 29 Phase 1; Immunology, Respiratory, Gastroenterology; next expected readout Nov 2026.

Receptor for both interleukin 4 and interleukin 13. Couples to the JAK1/2/3-STAT6 pathway. (UniProt, P24394)

Open in Phaseline: the race on IL4R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Brigham and Women's HospitalMIB 626 (NMN)
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2CPhase 4Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension …Nov 2026
Regeneron Pharmaceuticalsdupilumab
Interleukin-4 receptor subunit alpha antagonist
IL4RPhase 4Asthma; Chronic Obstructive Pulmonary Disease (COPD); Atopic Dermatitis; Eosinophilic Esophagitis (EoE) …Nov 2026
SanofiH5 Flu IMP 1
Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor
ROCK2, ROCK1, TNFSF4, CD38, IL4RPhase 4RSV Immunization; Diabetes Mellitus, Type 1; Asthma; Dermatitis Atopic …Dec 2026
Shanghai Chia Tai Tianqing Pharmaceutical Technology DevelopmentTQH2722 injection
Humanized interleukin-4 receptor alpha (IL-4Rα) monoclonal antibody
IL4RPhase 3Atopic Dermatitis; Seasonal Allergic RhinitisNov 2026
Guangdong Hengrui PharmaceuticalSHR-1819 Injection
IL-4 receptor alpha inhibitor
IL4RPhase 3Seasonal Allergic Rhinitis; Adolescents With Moderate-to-severe Atopic Dermatitis; Moderate-to-severe Atopic Dermatitis; Prurigo NodularisDec 2026
Jiangsu Genscend BiopharmaceuticalGS101 injection
IL-4 receptor alpha subunit antagonist
IL4RPhase 3Atopic Dermatitis (AD)Apr 2027
Université de SherbrookeCBD Oral Solution
FK506-binding protein 1A inhibitor
FKBP1A, PTGS2, IL4RPhase 3Asthma Control; Organ Transplant Failure or Rejection; Fragile X Syndrome; Triple-Negative Breast CancerJul 2028
Innovent Biologics (Suzhou)IBI3027
IL-4 receptor alpha antagonist (anti-IL-4Rα antibody)
IL4RPhase 3Atopic Dermatitis; Healthy VolunteersJul 2028
Keymed Biosciences Co.LtdCM310
IL-4 receptor (IL-4Rα) monoclonal antibody
IL4RPhase 3Atopic Dermatitis–
Genrix (Shanghai) BiopharmaceuticalGR1802
anti-IL4Rα monoclonal antibody
IL4RPhase 3Allergic Rhinitis, Seasonal; Chronic Rhinosinusitis With Nasal Polyps; Allergic Rhinitis–
Apogee TherapeuticsAPG777
IL-4 receptor antagonist
IL4RPhase 2Atopic Dermatitis; AsthmaNov 2026
Uniquity One (UNI)Solrikitug
IL-4 receptor alpha inhibitor
IL4RPhase 2COPD; Eosinophilic Esophagitis (EoE)Feb 2027
Beijing Tongren HospitalCM310
Interleukin-4 receptor antagonist
IL4RPhase 2Seasonal Allergic Rhinitis–

Conditions

Atopic Dermatitis (11) Asthma (8) Dermatitis Atopic (5) Ulcerative Colitis (4) Colitis Ulcerative (4) Nasal Polyps (4) Obstructive Sleep Apnea (4) Seasonal Allergic Rhinitis (3) Chronic Graft Versus Host Disease (3) Crohn's Disease (3) Plasma Cell Myeloma Refractory (3) Healthy Volunteers (3)

Modalities

small molecule (6), protein or peptide (4), antibody (2), mixed (1)

Companies

Apogee Therapeutics (1) Guangdong Hengrui Pharmaceutical (1) Sanofi (1) Université de Sherbrooke (1) Keymed Biosciences Co.Ltd (1) Regeneron Pharmaceuticals (1) Brigham and Women's Hospital (1) Shanghai Chia Tai Tianqing Pharmaceutical Technology Development (1) Innovent Biologics (Suzhou) (1) Uniquity One (UNI) (1) Jiangsu Genscend Biopharmaceutical (1) Genrix (Shanghai) Biopharmaceutical (1) Beijing Tongren Hospital (1)

Related targets

ROCK2 (1) ROCK1 (1) TNFSF4 (1) CD38 (1) FKBP1A (1) PTGS2 (1) SLC5A2 (1) SLC6A2 (1) GLP1R (1) UNKNOWN (1) Tubulin (1) OPRM1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.